This inventor holds 1 USPTO granted patent. Top assignee: Axys Pharmaceuticals, Inc.. Active years: 2003.
Company Filing History:
Years Active: 2003
Title: Neil Scott Cutshall: Innovator in Immunotherapy
Introduction
Neil Scott Cutshall is a notable inventor based in San Mateo, CA (US). He has made significant contributions to the field of immunotherapy, particularly in the treatment of inflammatory disorders. His innovative work has led to the development of novel compounds that address various health issues.
Latest Patents
Neil Scott Cutshall holds 1 patent for his invention titled "Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders." This patent describes compounds, compositions, and methods that are effective in preventing and treating mast-cell mediated inflammatory disorders. The compounds are particularly useful for addressing inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis. Additionally, they are effective for other immunomediated inflammatory disorders, including rheumatoid arthritis, conjunctivitis, and inflammatory bowel disease. The compositions include various forms of administration, such as oral, inhalant, topical, and parenteral preparations.
Career Highlights
Neil Scott Cutshall is associated with Axys Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His work focuses on creating effective treatments for inflammatory conditions, showcasing his commitment to improving patient outcomes.
Collaborations
Throughout his career, Neil has collaborated with esteemed colleagues, including Kenneth D Rice and Martin Sheringham Linsell. These partnerships have contributed to the success of his innovative projects and the advancement of therapeutic solutions.
Conclusion
Neil Scott Cutshall's contributions to immunotherapy highlight his role as a key innovator in the field. His patented work on benzimidazole compounds demonstrates his dedication to addressing significant health challenges. Through his career at Axys Pharmaceuticals, he continues to make strides in the treatment of inflammatory disorders.